ADE? Or ADR? Medication Error Case Studies for Successful EU Compliance

Quantity Discounts
1 - 9999
1 - 9999
1 - 9999
1 - 9999
1 - 9999
1 - 9999
Medication error is the 4th most common cause of death in the US. The UK loses $200,000,000 in treating medication errors from hospital funding EVERY year. Regulators are fed up and are making companies take responsibility for these errors. On June 6, the EU added medication errors as a new class of data that must be reported under Good Pharmacovigilance Practices Module VI. Are you prepared?

Two months ago, this wouldn’t have been your problem to report. Today it is!

Register Today

Drugmakers, contract manufacturers and physicians are always monitoring, investigating and reporting adverse drug events (ADEs) — only now drugmakers must report medication errors as adverse drug reactions (ADRs). Reporting is required as soon as possible, but no more than 15 calendar days after initial report to a pharmacovigilance center or to the marketing authorization holder.

Listen today as a top drug development consultant illustrates some of the many danger situations you may face.

These are case studies — actual, not hypothetical. Presenter Dr. Hoss Dowlat, Ph.D. has taken them from his 31+ years involved in drug development in the EU region and North America.

And that’s not all. You’ll discover the regulatory background behind this new EU crackdown, and how to shift your pharmacovigilance focus from products to patients. Check out this agenda:

  • Updates from the May 2013 EMA medication errors workshop
  • 9 factors that increase medication errors in the product lifecycle and special populations
  • What aspects of reporting have changed
  • What medication errors are, and why they weren’t formerly considered ADRs
  • Novel perspectives of EU vs. U.S. perspectives on medication safety
  • Why the EU is adopting the FDA’s risk mitigation tools
  • The EU patient leaflet — an overlooked opportunity for risk minimization?
  • And much more

One medication mixup that leads to hospitalization, disfigurement or death could cost millions upon millions of dollars. It’s not a risk worth taking. If you face EU drug regulation of any kind, for any reason, you owe it to yourself to sign up TODAY!

Here’s a suggested list of potential participants from your organization:

  • Regulatory affairs and compliance professionals
  • Risk management professionals
  • Clinical and drug safety/pharmcovigilance professionals
  • Medical affairs/medical safety professionals
  • Research and development professionals
  • Strategic planning and business development staff
  • Commercial affairs/business development executives
  • Legal staff
  • Executive management

Dr. Hoss Dowlat, Ph.D., VP-Regulatory Affairs, PharmBio Consulting. Dr. Dowlat has more than 31 years of drug development experience in more than 15 therapeutic areas in the European and North American pharmaceutical industries. Pharma and financial clients include more than 50 companies on three continents in search of strategic international regulatory support and due diligence. Dr. Dowlat is British-Canadian, educated in England to B.Sc. and Ph.D. level. He is a recipient of a post-doctoral European Royal Society Fellowship award in organic chemistry.

Register now!

Date: Sept. 2–20, 2013
Location: Your office or conference room (no need to travel!)
Time: Anytime

Gather your team for maximum benefit! Your investment is for one dial-in.

Interested in registering multiple sites?

Significant tuition discounts are available for three or more sites from
the same company. You must register at the same time and
provide a single payment to take advantage of the discount. Register below
by clicking on add to cart and then change your quantity in the shopping cart.
The discount will be calculated automatically.

3-4 sites – 10%
7-9 sites – 20%
5-6 sites – 15%
10+ sites – 25%

Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
with any questions.

We accept American Express, Visa and MasterCard. Make checks payable to FDAnews.

Or, register by phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600

Registrations may not be cancelled. Please contact customer service to make any substitutions.

Interested in Becoming a Speaker?
We're always looking for industry leaders eager to share their expertise at an FDAnews audioconference, webinar or physical conference. Our seasoned speaker community includes executives in the pharmaceutical, medical device and clinical trial industries, regulatory affairs, quality control, compliance, healthcare and academia, as well as several former — and current — top FDA officials. Click here to complete our speaker opportunity form and have a representative contact you about future opportunities.